Rybrevant 50 mg/ml Injection 7 ml used in the treatment of non-small cell lung cancer (NSCLC). It contains amivantamab, which works by blocking the signals that help cancer cells grow and divide. Common side effects may include rash, itching, muscle/joint pain, edema, shortness of breath, cough, constipation, changes in vision, chest discomfort, fever, and flushing. Inform the doctor if you are pregnant, breastfeeding, taking other medicines or have pre-existing medical conditions.